As demand for our QTc studies grows, we recently introduced new Holter and Telemetry equipment to enhance this crucial new service.
Adam Walker, Head of Richmond’s Data Management department, completed this year’s Flora London Marathon in 4 hours and 39 minutes! Adam raised £2,500 for the charity ‘Bliss’, but first he had to run 26.2 miles.
We are delighted to announce that we have opened a new facility at Mayday University Hospital to complement our units and offices in St George’s Hospital and St George’s University of London. This ground breaking move means Richmond Pharmacology is the UK’s first CRO with a dedicated Phase I and clinical trials unit to be based in 2 acute NHS Teaching Hospitals.
We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities.
We are delighted to announce that Mayday University Hospital NHS Trust was recently issued an annual performance rating of 3 stars, which places them in the top 28% of Trusts in the UK.
We have great pleasure in announcing that we are officially operating in our 5th year of clinical trials. Richmond Pharmacology was formed in August 2001, since when we have grown to become the largest Phase I–IV Clinical Trials Centre in the UK, with a well earned reputation for specialties such as QTc Studies and Bridging Studies, and more recently Patient Studies across numerous therapeutic areas.
The Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.